Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Darovasertib · IDE-196, LXS-196

Small molecule · Inhibitor of Protein kinase C · developed by IDEAYA Biosciences

Phase 3 Most advanced trial
IDYA Developer
2 Registered trials

What is Darovasertib?

Darovasertib is an orally available small molecule that binds and inhibits protein kinase C (PKC), a serine/threonine kinase involved in tumor cell proliferation, invasion and survival. It is being studied in metastatic uveal melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IDE-196, LXS-196
Drug type
Small molecule
Targets
Protein kinase C
Mechanism
Inhibitor of Protein kinase C
Pathways
PKC-mediated signaling, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
E0YF0M8O09

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07015190 Phase 3 Uveal Melanoma Recruiting IDYA
NCT05987332 Phase 2/3 Metastatic Uveal Melanoma Active not recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Uveal MelanomaUveal Melanoma

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind Darovasertib

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.